Q2 2025 Management View CEO Matthew Kapusta highlighted that "the first half of 2025 has been tremendously productive for the company as we advance AMT-130 towards potentially becoming the first ...

Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 top ...

Investing.com - uniQure N.V. (NASDAQ: QURE) reported second quarter revenue that fell short of analyst expectations, though its loss per share was narrower than anticipated. The gene therapy company’s ...

Qure (QURE) delivered earnings and revenue surprises of +22.47% and -26.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

AMSTERDAM (AP) — AMSTERDAM (AP) — UniQure NV (QURE) on Tuesday reported a loss of $37.7 million in its second quarter. On a per-share basis, the Amsterdam-based company said it had a loss of 69 cents.

Qure (NASDAQ:QURE) is scheduled to announce Q2 earnings results on Tuesday, July 29th, before market open. The consensus EPS ...

uniQure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges despite strong clinical data.

uniQure N.V. (QURE) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.

The stock price of uniQure, a gene therapy company, has seen a rise of 20% in a week, while it is up 10% over the last month. The recent rise can be attributed to its Q3 loss of $0.79 per share ...

The uniQure gene therapy is being tested in an open-label Phase 3 study that dosed 54 patients, each of them given a single infusion. The main goal was to measure FIX levels at 26 weeks.

The stock price of uniQure stock, a gene therapy company, has seen a a large 13% drop over the last five trading days. The company recently announced that the U.S. FDA has asked for eighteen ...

The stock price of uniQure (NASDAQ:QURE), a gene therapy company, has seen a rise of 20% in a week, while it is up 10% over the last month. The recent rise can be attributed to its Q3 loss of $0. ...